19.09.2018: Joint Marketing and Sales Promotion with Ncardia
Nanion Technologies and Ncardia Sign Co-Marketing and Support Agreement to enhance Options for Cardiac Researchers
Munich, Germany and Cologne, Germany, September 19, 2018;
Nanion Technologies GmbH, a leading provider of instrumentation for ion channel drug discovery and screening, and the Ncardia Group, a leading developer, manufacturer, and service provider of human induced pluripotent stem cells (iPSCs) for safety and efficacy testing announced today that they have entered into a joint marketing and sales promotion agreement.
Click here to read the full press release.